Mainz Biomed N.V. (QUCY) - Total Assets
Based on the latest financial reports, Mainz Biomed N.V. (QUCY) holds total assets worth $5.33 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See QUCY net asset value for net asset value and shareholders' equity analysis.
Mainz Biomed N.V. - Total Assets Trend (2021–2025)
This chart illustrates how Mainz Biomed N.V.'s total assets have evolved over time, based on quarterly financial data.
Mainz Biomed N.V. - Asset Composition Analysis
Current Asset Composition (December 2025)
Mainz Biomed N.V.'s total assets of $5.33 Million consist of 34.6% current assets and 65.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.7% |
| Accounts Receivable | $17.35K | 0.3% |
| Inventory | $216.89K | 4.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.11 Million | 20.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Mainz Biomed N.V.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Mainz Biomed N.V. (QUCY) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mainz Biomed N.V.'s current assets represent 34.6% of total assets in 2025, a decrease from 95.7% in 2021.
- Cash Position: Cash and equivalents constituted 16.7% of total assets in 2025, down from 86.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 20.9% of total assets.
Mainz Biomed N.V. Competitors by Total Assets
Key competitors of Mainz Biomed N.V. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €84.58 Million |
|
Inoviq Ltd
AU:IIQ
|
Australia | AU$24.52 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Imagion Biosystems Ltd
AU:IBX
|
Australia | AU$932.48K |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
Mainz Biomed N.V. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.50 | 1.32 | 0.24 |
| Quick Ratio | 0.44 | 1.26 | 0.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.85 Million | $1.89 Million | $-7.62 Million |
Mainz Biomed N.V. - Advanced Valuation Insights
This section examines the relationship between Mainz Biomed N.V.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.14 |
| Latest Market Cap to Assets Ratio | 0.96 |
| Asset Growth Rate (YoY) | -59.8% |
| Total Assets | $5.33 Million |
| Market Capitalization | $5.14 Million USD |
Valuation Analysis
Near Book Valuation: The market values Mainz Biomed N.V.'s assets close to their book value (0.96x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Mainz Biomed N.V.'s assets decreased by 59.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mainz Biomed N.V. (2021–2025)
The table below shows the annual total assets of Mainz Biomed N.V. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $5.33 Million | -59.76% |
| 2024-12-31 | $13.24 Million | -14.09% |
| 2023-12-31 | $15.41 Million | -23.87% |
| 2022-12-31 | $20.24 Million | +101.59% |
| 2021-12-31 | $10.04 Million | -- |
About Mainz Biomed N.V.
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more